-

11:24:10 AM

ICU Stock News

ICU - SeaStar Medical Holding Corp

03/16/23 8:00 AM

Nasdaq : ICU

low float

SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private Placement

SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced the signing and closing of

RHEA-AI

neutral

03/15/23 4:05 PM

Nasdaq : ICU

conferenceslow float

SeaStar Medical to Present at the Emerging Growth Virtual Conference on March 22, 2023

SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, Chief

RHEA-AI

neutral

02/24/23 8:05 AM

Nasdaq : ICU

low float

SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit

SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Kevin Chung, M.D., Chief

RHEA-AI

neutral

02/15/23 4:01 PM

Nasdaq : ICU

low float

SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury

SeaStar Medical (Nasdaq: ICU), a medical device company

RHEA-AI

neutral

02/14/23 4:05 PM

Nasdaq : ICU

low float

SeaStar Medical to Hold Business Update Conference Call on February 15, 2023

SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces it will hold a conference call to discuss business updates including the recent FDA

RHEA-AI

neutral

02/09/23 8:19 AM

Nasdaq : ICU

fda approvallow float

SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

SeaStar Medical (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces today that the

RHEA-AI

neutral

01/31/23 8:00 AM

Nasdaq : ICU

conferenceslow float

SeaStar Medical to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023

SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will present a company overview at the virtual Sequire

RHEA-AI

neutral

01/09/23 8:25 AM

Nasdaq : ICU

low float

SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the

RHEA-AI

neutral

12/29/22 8:30 AM

Nasdaq : ICU

low float

SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)

SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) and Nuwellis, Inc. announce an exclusive U.S. license and

RHEA-AI

neutral

12/02/22 9:05 AM

Nasdaq : ICU

low float

SeaStar Medical Bolsters Operational Expertise with Appointment of Thomas R. Mullen as Vice President of Operations and Product Development

SeaStar Medical Holding Corporation (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced the

RHEA-AI

positive